HKSE · 0013.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 02:41 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
HUTCHMED (China) Limited’s quoted price sits in the upper half of its reported 52-week range, 17.59% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
HUTCHMED (China) Limited’s next earnings report is currently expected on Mar 4, 2027, with estimated earnings per share of HK$0.33. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow HUTCHMED (China) Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
HUTCHMED (China) Limited, a biopharmaceutical company established in 2000 and headquartered in Central, Hong Kong, focuses on the discovery, development, and commercialization of innovative targeted therapies and immunotherapies. The company primarily addresses cancer and immunological disorders, serving a global patient population in addition to Hong Kong. Its operations are structured into two main segments: Oncology/Immunology and Other Ventures. The company boasts an extensive pipeline of drug candidates. Key assets include Savolitinib, an inhibitor developed for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC). Fruquintinib targets CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and a broad spectrum of gastrointestinal and solid tumors. Another prominent compound, Surufatinib, is indicated for various neuroendocrine tumors (NETs) including pancreatic and non-pancreatic types, alongside biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and other solid tumors. Further pipeline assets feature HMPL-523, a spleen tyrosine kinase (Syk) inhibitor for treating hematological cancers and certain chronic immune diseases; HMPL-689, an inhibitor specifically targeting the PI3Kd isoform; and Tazemetostat, an EZH2 inhibitor utilized in the treatment of specific epithelioid sarcoma and follicular lymphoma patients. The company's development efforts also encompass HMPL-306 for hematological malignancies, gliomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase (BTK) inhibitor; HMPL-453, aimed at intrahepatic cholangiocarcinoma; HMPL-295 for various solid tumors; HMPL-653, developed for metastatic solid tumors and tenosynovial giant cell tumors; and the inhibitors Epitinib (HMPL-813) and Theliatinib (HMPL-309). HUTCHMED has forged strategic collaboration agreements with a number of significant pharmaceutical entities, including AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company, originally known as Hutchison China MediTech Limited, officially changed its name to HUTCHMED (China) Limited in May 2021.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:57 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2024 | Sep 30, 2024 | HK$0.05 | HK$1.26B |
|---|
| Q2 2024 | Jul 31, 2024 | HK$0.12+119.11% vs estimate | HK$2.39B-4.27% vs estimate |
|---|
| Q1 2024 | Jun 11, 2024 | HK$0.12+157.54% vs estimate | HK$1.20B+184.24% vs estimate |
|---|
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$436.40-HK$1.40 (-0.32%)
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 22.42% below the high.
HK$82.35-HK$1.15 (-1.38%)
Akeso, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.21% below the high.
HK$49.36-HK$0.56 (-1.12%)
Shanghai Henlius Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.33% below the high.
HK$17.44-HK$0.24 (-1.36%)
Zai Lab Limited’s quoted price sits in the upper half of its reported 52-week range, 18.58% below the high.
HK$11.39-HK$0.28 (-2.4%)
InnoCare Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 29.69% below the high.
HK$24.32-HK$0.64 (-2.56%)
GenFleet Therapeutics (Shanghai) Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.03% below the high.
HK$4.90+HK$0.17 (+3.48%)
CStone Pharmaceuticals’s quoted price sits in the lower half of its reported 52-week range, 52.93% below the high.
HK$2.84+HK$0.02 (+0.53%)
Antengene Corporation Limited’s quoted price sits in the lower half of its reported 52-week range, 54.78% below the high.
